Considering studies in mice and humans, it seems that even moderate up-regulation of Nrf2 activates both anti-inflammatory and anti-oxidant systems and might represent the target for new additional therapeutic strategies in SLE [38,39]. The gene discussed is NFE2L2; the disease is systemic lupus erythematosus.